ArticleJournal of extracellular biology2026
Macromolecule-Loaded Hybrid Extracellular Vesicles via Ionic Lipid-Based Post-Loading for Intracellular Delivery: Functional Evaluation for Neurodegenerative Therapy.
Article in Journal of extracellular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) are natural carriers that show promise as drug delivery systems (DDS). We developed a non-invasive post-loading method to encapsulate macromolecules in EVs using our proprietary ionic lipid base (ILB), which enables electrostatically driver hybridisation without disrupting EV structure. Using EVs isolated from bovine milk and adipocyte-derived mesenchymal stem cell culture medium, hybrid-EVs (H-EV) with different ILB contents encapsulating protein or nucleic acid molecules for delivery were produced in a reproducible manner. The H-EV retained EV surface markers comparable to those of native EVs after preparation. After cellular uptake, the encapsulated molecules escaped from endosomes into the cytoplasm and exhibited intended functions. In an experiment using SH-SY5Y neuroblastoma cells in which α-synuclein (αSyn) aggregation was induced, the introduction of H-EV encapsulating anti-αSyn antibodies (Abs) significantly suppressed αSyn aggregation. Furthermore, delivery of anti-phospho-AKT Abs using H-EV promoted caspase 3/7 activity and cell apoptosis. Intravenous administration of H-EV encapsulating a model Ab into mice resulted in detectable Ab signals in the cerebral cortex, cerebellum, hippocampus and other cells associated with neurodegenerative diseases within 24 h, as assessed by ex vivo imaging. H-EV enabled loading of various molecules and their targeted transport to specific organs and the cytoplasm, highlighting their potential as a versatile platform for Ab therapies targeting intracellular proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.